Eric Schoen Purchases 10,000 Shares of Cassava Sciences Inc (SAVA) Stock

Cassava Sciences Inc (NASDAQ:SAVA) CFO Eric Schoen acquired 10,000 shares of the business’s stock in a transaction that occurred on Tuesday, May 14th. The shares were acquired at an average cost of $1.06 per share, for a total transaction of $10,600.00. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Shares of NASDAQ:SAVA traded up $0.02 during trading on Friday, reaching $1.09. The stock had a trading volume of 89,906 shares, compared to its average volume of 65,177. Cassava Sciences Inc has a 52 week low of $0.76 and a 52 week high of $10.80.

Cassava Sciences (NASDAQ:SAVA) last released its quarterly earnings results on Monday, April 29th. The company reported ($0.08) EPS for the quarter.

COPYRIGHT VIOLATION NOTICE: “Eric Schoen Purchases 10,000 Shares of Cassava Sciences Inc (SAVA) Stock” was originally posted by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are reading this piece of content on another publication, it was stolen and republished in violation of U.S. and international copyright law. The original version of this piece of content can be viewed at

Cassava Sciences Company Profile

Cassava Sciences, Inc, a clinical-stage drug development company, develops drugs for nervous system disorders. The company's lead therapeutic product candidate PTI-125, a small molecule drug that is in Phase II clinical trial for the treatment of Alzheimer's disease. It is also developing PTI-125Dx, a blood-based biomarker/diagnostic to detect Alzheimer's disease.

Featured Article: Why do companies issue convertible shares?

Receive News & Ratings for Cassava Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cassava Sciences and related companies with's FREE daily email newsletter.